These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1074 related articles for article (PubMed ID: 33737337)

  • 1. GD2 redirected CAR T and activated NK-cell-mediated secretion of IFNγ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape.
    Caforio M; Sorino C; Caruana I; Weber G; Camera A; Cifaldi L; De Angelis B; Del Bufalo F; Vitale A; Goffredo BM; De Vito R; Fruci D; Quintarelli C; Fanciulli M; Locatelli F; Folgiero V
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells.
    Lee MY; Robbins Y; Sievers C; Friedman J; Abdul Sater H; Clavijo PE; Judd N; Tsong E; Silvin C; Soon-Shiong P; Padget MR; Schlom J; Hodge J; Hinrichs C; Allen C
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CAR T-cell-mediated delivery of bispecific innate immune cell engagers for neuroblastoma.
    Pascual-Pasto G; McIntyre B; Hines MG; Giudice AM; Garcia-Gerique L; Hoffmann J; Mishra P; Matlaga S; Lombardi S; Shraim R; Schürch PM; Yarmarkovich M; Hofmann TJ; Alikarami F; Martinez D; Tsang M; Gil-de-Gómez L; Spear TT; Bernt KM; Wolpaw AJ; Dimitrov DS; Li W; Bosse KR
    Nat Commun; 2024 Aug; 15(1):7141. PubMed ID: 39164224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Druggable epigenetic suppression of interferon-induced chemokine expression linked to
    Seier JA; Reinhardt J; Saraf K; Ng SS; Layer JP; Corvino D; Althoff K; Giordano FA; Schramm A; Fischer M; Hölzel M
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34016720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transition to a mesenchymal state in neuroblastoma may be characterized by a high expression of GD2 and by the acquisition of immune escape from NK cells.
    Di Matteo S; Bilotta MT; Pelosi A; Haas D; Theinert T; Weber G; Schlegel PG; Berg M; Moretta L; Maggi E; Azzarone B; Vacca P; Tumino N; Caruana I
    Front Immunol; 2024; 15():1382931. PubMed ID: 38736882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced anti-tumor activity mediated by combination chimeric antigen receptor T cells targeting GD2 and GPC2 in high-risk neuroblastoma.
    Wu H; Zhang G; Liu Z; Liu W; Wang X; Zhao Y
    Cytotherapy; 2024 Nov; 26(11):1308-1319. PubMed ID: 38904586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model.
    Richman SA; Nunez-Cruz S; Moghimi B; Li LZ; Gershenson ZT; Mourelatos Z; Barrett DM; Grupp SA; Milone MC
    Cancer Immunol Res; 2018 Jan; 6(1):36-46. PubMed ID: 29180536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of neuroblastoma cell lines with uncommon TAZ
    Canzonetta C; Pelosi A; Di Matteo S; Veneziani I; Tumino N; Vacca P; Munari E; Pezzullo M; Theuer C; De Vito R; Pistoia V; Tomao L; Locatelli F; Moretta L; Caruana I; Azzarone B
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33452207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.
    Parihar R; Rivas C; Huynh M; Omer B; Lapteva N; Metelitsa LS; Gottschalk SM; Rooney CM
    Cancer Immunol Res; 2019 Mar; 7(3):363-375. PubMed ID: 30651290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eradication of Neuroblastoma by T Cells Redirected with an Optimized GD2-Specific Chimeric Antigen Receptor and Interleukin-15.
    Chen Y; Sun C; Landoni E; Metelitsa L; Dotti G; Savoldo B
    Clin Cancer Res; 2019 May; 25(9):2915-2924. PubMed ID: 30617136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing.
    Prapa M; Caldrer S; Spano C; Bestagno M; Golinelli G; Grisendi G; Petrachi T; Conte P; Horwitz EM; Campana D; Paolucci P; Dominici M
    Oncotarget; 2015 Sep; 6(28):24884-94. PubMed ID: 26298772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma.
    Seidel D; Shibina A; Siebert N; Wels WS; Reynolds CP; Huebener N; Lode HN
    Cancer Immunol Immunother; 2015 May; 64(5):621-34. PubMed ID: 25711293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-L1-expressing natural killer cells predict favorable prognosis and response to PD-1/PD-L1 blockade in neuroblastoma.
    Song M; Huang Y; Hong Y; Liu J; Zhu J; Lu S; Wang J; Sun F; Huang J; Xu J; Tang Y; Xia JC; Zhang Y
    Oncoimmunology; 2024; 13(1):2289738. PubMed ID: 38125723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced
    Xu X; Huang W; Heczey A; Liu D; Guo L; Wood M; Jin J; Courtney AN; Liu B; Di Pierro EJ; Hicks J; Barragan GA; Ngai H; Chen Y; Savoldo B; Dotti G; Metelitsa LS
    Clin Cancer Res; 2019 Dec; 25(23):7126-7138. PubMed ID: 31484667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Indoleamine 2,3-Dioxygenase 1 Inhibitor-Loaded Nanosheets Enhance CAR-T Cell Function in Esophageal Squamous Cell Carcinoma.
    Shao J; Hou L; Liu J; Liu Y; Ning J; Zhao Q; Zhang Y
    Front Immunol; 2021; 12():661357. PubMed ID: 33828565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma.
    Moghimi B; Muthugounder S; Jambon S; Tibbetts R; Hung L; Bassiri H; Hogarty MD; Barrett DM; Shimada H; Asgharzadeh S
    Nat Commun; 2021 Jan; 12(1):511. PubMed ID: 33479234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A transplantable TH-MYCN transgenic tumor model in C57Bl/6 mice for preclinical immunological studies in neuroblastoma.
    Kroesen M; Nierkens S; Ansems M; Wassink M; Orentas RJ; Boon L; den Brok MH; Hoogerbrugge PM; Adema GJ
    Int J Cancer; 2014 Mar; 134(6):1335-45. PubMed ID: 24038106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymorphonuclear myeloid-derived suppressor cells impair the anti-tumor efficacy of GD2.CAR T-cells in patients with neuroblastoma.
    Tumino N; Weber G; Besi F; Del Bufalo F; Bertaina V; Paci P; Quatrini L; Antonucci L; Sinibaldi M; Quintarelli C; Maggi E; De Angelis B; Locatelli F; Moretta L; Vacca P; Caruana I
    J Hematol Oncol; 2021 Nov; 14(1):191. PubMed ID: 34772439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of MEK pathway enhances the antitumor efficacy of chimeric antigen receptor T cells against neuroblastoma.
    Tomida A; Yagyu S; Nakamura K; Kubo H; Yamashima K; Nakazawa Y; Hosoi H; Iehara T
    Cancer Sci; 2021 Oct; 112(10):4026-4036. PubMed ID: 34382720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers.
    Fischer-Riepe L; Kailayangiri S; Zimmermann K; Pfeifer R; Aigner M; Altvater B; Kretschmann S; Völkl S; Hartley J; Dreger C; Petry K; Bosio A; von Döllen A; Hartmann W; Lode H; Görlich D; Mackensen A; Jungblut M; Schambach A; Abken H; Rossig C
    Clin Cancer Res; 2024 Aug; 30(16):3564-3577. PubMed ID: 38593230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.